Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% – Should You Sell?

Posted by Francis Steltz on Aug 7th, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) traded down 6.1% during trading on Friday . The company traded as low as $27.25 and last traded at $27.24. 482,758 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 3,543,647 shares. The stock had previously closed at $29.00.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics in a research report on Wednesday, July 15th. They set an “overweight” rating and a $46.00 price target on the stock. Raymond James Financial lowered shares of Tango Therapeutics to a “hold” rating in a research note on Thursday, June 25th. B. Riley Financial restated a “buy” rating on shares of Tango Therapeutics in a report on Monday, June 8th. Canaccord Genuity Group upped their price target on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, UBS Group set a $55.00 price target on Tango Therapeutics in a report on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.15.

Read Our Latest Report on Tango Therapeutics

Tango Therapeutics Trading Down 7.0%

The firm’s fifty day moving average is $28.37 and its 200-day moving average is $21.73. The stock has a market capitalization of $3.90 billion, a PE ratio of -32.48 and a beta of 1.16.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). As a group, equities analysts predict that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Insider Activity at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total transaction of $798,930.00. Following the completion of the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its stake in Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Tango Therapeutics by 26.7% in the 4th quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock valued at $87,000 after buying an additional 2,065 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after buying an additional 2,243 shares during the period. SG Americas Securities LLC grew its position in shares of Tango Therapeutics by 10.2% during the first quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock worth $507,000 after buying an additional 2,251 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Tango Therapeutics by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock worth $10,237,000 after buying an additional 2,272 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.